Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Visolis has successfully scaled its technology to ton-level manufacturing, delivered on-spec products to early customers, secured multi-million-dollar joint development agreements, achieved multi-millions in annual revenue, and is preparing to launch its first large-scale commercial facility in 2025—a 40X scale-up from current operations. The company’s platform produces sustainable aviation fuel (SAF), synthetic rubber precursors like bio-isoprene, non-toxic solvents, synthetic latexes, and other specialty/commodity chemicals with lower cost and carbon footprint than traditional processes. Visolis’ SAF offers higher energy density than many alternatives. Its process uses waste biomass or CO₂ as feedstock via engineered microbes followed by chemical catalysis for efficient production at scale. The company recently received a $2.25M U.S. Department of Defense award for domestic manufacturing expansion. No clinical results are relevant.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Visolis.